Explore how reverse mergers let private companies go public efficiently. Understand the benefits and risks of this alternative to traditional IPOs.

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly ...

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

Rallybio has inked a deal to combine with fellow clinical-stage biotechnology company Candid Therapeutics in an all-stock reverse merger. Rallybio on Monday said its shareholders will own about 3.65% ...

Discover why reverse mergers are a faster, less costly way for private companies to go public compared to IPOs.

US biotechnology company Candid Therapeutics will go public through a reverse merger with US rare disease drugmaker Rallybio ...

Over a year after first agreeing to a reverse merger with Pulmatrix, protein degradation biotech Cullgen has instead opted to be bought by Gyre Therapeutics in a ...

Keto Motors plans a reverse merger with Taza International as Tron Energy takes a 10% stake, backing its ₹300 crore Telangana electric bus plant.

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat ...

In Brief Animoca Brands plans a Nasdaq listing via a reverse merger with Currenc Group Inc., aiming for a $2.4 billion valuation. Post-merger, Animoca shareholders will own 95% of the newly formed ...

A special purpose acquisition company (SPAC) is a blank-check company with no business operations, formed to raise capital through an initial public offering (IPO) for the purpose of effecting a ...

Pulmatrix Inc. has announced the termination of its Merger Agreement with Cullgen Inc., which was announced in November 2024.